Published Technical Disclosure Archive

Personalized Bio-Orthogonal Drug Activation Platform

Publication ID: 24-11857636_0010_PTD
Published: October 28, 2025
Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Personalized Bio-Orthogonal Drug Activation Platform,” Published Technical Disclosure No. 24-11857636_0010_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857636_0010_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,636.

Summary of the Inventive Concept

A next-generation bio-orthogonal drug activation system leveraging AI, quantum computing, and decentralized networks to optimize and adapt reaction conditions for personalized medicine.

Background and Problem Solved

The original patent disclosed bio-orthogonal drug activation methods using abiotic chemical reactions. However, these methods have limitations in terms of specificity, adaptability, and real-time monitoring. The new inventive concept addresses these limitations by incorporating advanced technologies to create a personalized, adaptive, and real-time bio-orthogonal drug activation platform.

Detailed Description of the Inventive Concept

The platform consists of a bio-orthogonal drug activation module, which utilizes machine learning algorithms to optimize the retro Diels-Alder reaction for a specific patient's condition. Real-time monitoring is enabled through wearable sensors and artificial intelligence, allowing for adjustments to the reaction conditions. Additionally, the platform incorporates quantum computing to simulate and predict optimal reaction conditions for a wide range of prodrugs and diseases. The system can be integrated into modular, implantable devices or decentralized networks, enabling swarm intelligence and real-time adaptation across a population of patients.

Novelty and Inventive Step

The new inventive concept's use of AI, quantum computing, and decentralized networks to optimize and adapt bio-orthogonal drug activation reaction conditions in real-time, for personalized medicine, is a novel and non-obvious advancement over the original patent.

Alternative Embodiments and Variations

Alternative embodiments may include the use of different machine learning algorithms, integration with other advanced technologies such as nanotechnology or bioprinting, or adaptation to different disease areas or patient populations.

Potential Commercial Applications and Market

The personalized bio-orthogonal drug activation platform has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of precision medicine, targeted therapies, and real-time monitoring. The market for such a platform is expected to be substantial, given the growing demand for personalized and adaptive healthcare solutions.

CPC Classifications

SectionClassGroup
A A61 A61K47/6803
A A61 A61K31/435
A A61 A61K31/444
A A61 A61K31/704
A A61 A61K38/05
A A61 A61K39/3955
A A61 A61K39/39558
A A61 A61K47/22
A A61 A61K47/545
A A61 A61K47/555
A A61 A61K47/558
A A61 A61K47/6897
B B82 B82Y5/00
C C07 C07C33/16
C C07 C07D237/26
C C07 C07D257/08
Y Y02 Y02A50/30

Field of Art

Pharmaceutical biotechnology, specifically bio-orthogonal drug activation systems, involving advanced drug delivery, chemical modification of pharmaceuticals, and personalized medicine technologies

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in pharmaceutical chemistry, biotechnology, or chemical engineering, possessing expertise in prodrug design, bio-orthogonal reactions, machine learning applications in drug delivery, and familiarity with emerging personalization technologies

Obviousness Rationale

A PHOSITA would recognize that integrating machine learning, quantum computing, and real-time monitoring into bio-orthogonal drug activation represents a predictable technological progression from existing prodrug activation methods. The core bio-orthogonal reaction principles remain consistent, with the proposed variations representing incremental improvements in monitoring, optimization, and personalization. The technical challenges of adapting drug activation to individual patient conditions would be viewed as a natural extension of existing targeted drug delivery research.

Obvious Combinations & Variations

Source Patent Element
Bio-orthogonal chemical reaction for drug activation
PTD Variation
Machine learning optimization of retro Diels-Alder reaction conditions
Obviousness Reasoning
Applying computational intelligence to optimize chemical reactions is a known technique in pharmaceutical engineering, representing a predictable application of machine learning to existing reaction parameters
Source Patent Element
Targeted drug delivery mechanism
PTD Variation
Real-time monitoring through wearable sensors and AI adaptation
Obviousness Reasoning
Continuous monitoring and dynamic adjustment of drug activation represents an obvious technological progression in personalized medicine, utilizing standard sensor and machine learning technologies
Source Patent Element
Prodrug activation through chemical transformation
PTD Variation
Quantum computing simulation of reaction conditions across multiple drug candidates
Obviousness Reasoning
Computational modeling of chemical reactions is a well-established technique, and extending this to quantum computing represents a logical technological advancement with predictable potential improvements
Source Patent Element
Chemical modification of inactive drug compounds
PTD Variation
Decentralized network for adaptive drug activation across patient populations
Obviousness Reasoning
Collective intelligence and networked medical technologies are emerging standard approaches in personalized medicine, representing an obvious extension of existing drug delivery research
Source Patent Element
Site-specific drug activation mechanism
PTD Variation
Modular, implantable microfluidic device with nanoscale reaction chamber
Obviousness Reasoning
Miniaturization and localized drug delivery are known technological trends, with the proposed device representing a predictable engineering solution for targeted drug activation
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857636 and the disclosed technological variations, a person having ordinary skill in the art would find the proposed bio-orthogonal drug activation platform with machine learning, quantum computing, and adaptive monitoring technologies to be obvious variations of existing prodrug activation methods. The incremental technological improvements represent predictable applications of known techniques in pharmaceutical engineering and personalized medicine, thereby rendering potential patent claims obvious under 35 U.S.C. Section 103.

Original Patent Information

Patent NumberUS 11,857,636
TitleBio-orthogonal drug activation
Assignee(s)Tagworks Pharmaceuticals B.V.